Cleveland-area SPR Therapeutics is tackling the chronic pain market with its Smartpatch technology. The Smartpatch external stimulator delivers an electrical signal to an electrode placed in the muscle. The electrical signals stimulate the target nerve within the muscle, thereby exercising the muscle to treat the pain. The Smartpatch system will serve the $150 billion pain market, in particular those suffering shoulder pain from strokes, as well as chronic lower back pain.

"It's a very simple short-term therapy that can eliminate chronic pain," says Maria Bennett, president and CEO of SPR. "It can be administered by a surgeon or non-surgeon, has no side effects and is completely reversible."

The company, which was founded in January 2010, is a spinoff of NDI Medical, which developed the technology and licensed it SPR. JumpStart Ventures announced last week that it will invest $250,000 in SPR Therapeutics to help bring the technology to market later this year or in early 2012.

"JumpStart's investment really allows us to complete the commercialization," says Bennett. "It helps us get to market, be prepared with all the pieces and parts so we can really hit the ground running."

Meant for use up to 30 days, Smartpatch has also demonstrated long-term pain relief. The company's series of clinical feasibility studies demonstrated that, at the end of the short-term therapy, 84 percent of patients experienced a significant reduction in pain and 40 percent were pain free. After completing the Smartpatch therapy, 78 percent of these patients continued to have significant pain relief.


Source: Maria Bennett
Writer: Karin Connelly